Search filters
Filters
Clear All

Phase

  • 183
  • 156
  • 2
  • 194
  • 1
  • 148
  • 17
  • 396
  • 1237
  • 588
  • 29
  • 49
  • 3
  • 1162
  • 1237
  • 6
  • 3
  • 1240

Found 1243 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 07419: A Phase 1b/2a Multicenter Open-Label Dose Escalation Study to Determine the Maximum Tolerated Dose Assess the Safety Tolerability Pharmacokinetics and Efficacy Of Cc-220 Monotherapy and In Combination With Other Treatments In Subjects With Relapsed and Refractory Multiple Myeloma

99 years or below
All genders
Phase 2
The purpose of this study is to test the safety of an experimental drug CC-220, alone and in combination with other treatments. The study is also designed to define the appropriate dose for further testing of the study drug and these experimental combinations.
Learn More

UPCC 03920: A Phase 1/1b Open-label Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors

99 years or below
All genders
Phase 1
This is a Phase 1 study that will evaluate the effectiveness of TPST-1120. Subjects may receive TPST-1120 alone or in combination with nivolumab. Subjects eligible to participate are those with advanced solid tumors.
Learn More

UPCC 08320 Phase 3 Randomized Double-blind Multicenter Global Study of Monalizumab or Placebo in Combination with Cetuximab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated with an Immune Checkpoint Inhibitor

99 years or below
All genders
TBD
Learn More

UPCC 05720: Enhance: A Randomized Double-blind Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-na ve Patients with Higher Risk Myelodysplastic Syndrome

99 years or below
All genders
TBD
Learn More
RADVAX FOR RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA: A PHASE II TRIAL OF PEMBROLIZUMAB + LOW DOSE RADIOTHERAPY

RADVAX FOR RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA: A PHASE II TRIAL OF PEMBROLIZUMAB + LOW DOSE RADIOTHERAPY

18 years - 99 years
All genders
Phase 2
This study plans to treat subjects with pembrolizumab by infusion in combination with radiation therapy to see if the combination is an effective treatment for relapsed/refractory non-Hodgkin lymphoma. Radiation therapy is commonly used to treat relapsed/refractory non-Hodgkin lymphoma. Although pembrolizumab is FDA-approved for some cancers, including Hodgkin lymphoma, it is …
Learn More
S1900B A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

S1900B A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

18 years - 99 years
All genders
Phase 2
This phase II LUNG-MAP treatment trial studies how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer that is stage IV or has come back (recurrent). Selpercatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Learn More
ASPEN- A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis

ASPEN- A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis

18 years - 85 years
All genders
Phase 3
Interventional
Penn Medicine patients already participating in protocol INS1007 301 will be invited to participate in this study. The Pharmacokinetic (PK) portion of this substudy is designed to evaluate the amount of brensocatib present in your blood at certain time periods before and after the study drug is administered, and the …
Learn More
A Randomized study of EHR Defaults and Using social Comparison feedback to Effectively decrease opioid prescription pill burden - The REDUCE Trial

A Randomized study of EHR Defaults and Using social Comparison feedback to Effectively decrease opioid prescription pill burden - The REDUCE Trial

99 years or below
All genders
Observational
Opioid-related abuse and overdose represent a growing national epidemic in the United States. Clinician practice patterns play an important role: opioid prescriptions impact the likelihood that patients will misuse or become dependent on these medications, with longer prescriptions leading to greater sustained use. In this study, we will evaluate a …
Learn More

UPCC 02521 A Randomized Phase II Trial of Cabozantinib Combined with PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

99 years or below
All genders
Phase 2
This research study is designed to learn more about how soft tissue sarcomas respond to treatment with different sequences of a combination of three drugs: cabozantinib, nivolumab, and ipilimumab when given to individuals who have been diagnosed with Metastatic Soft Tissue Sarcoma.
Learn More
EMPACT-MI

EMPACT-MI

65 years - 99 years
All genders
Phase 3
This clinical trial is enrolling participants that have had a heart attack, (also called acute myocardial infarction or MI). Even though treatments have made progress, researchers are still trying to improve care for heart attack patients, who are at increased risk for heart failure and death. The purpose of this …
Learn More
971 - 980 of 1243